Vojmir Urlep receives a plaque "Pro Universitate Labacensi" for his significant contribution to the reputation of the University of Ljubljana in the international arena

  • Vojmir Urlep, President of the Board of Management of Lek and Novartis Country President, Slovenia, received the »Pro Universitate Labacensi« plaque for his successful longstanding cooperation with the Faculty of Pharmacy of the University of Ljubljana.
  • The award is a testament to Lek's close cooperation with the University of Ljubljana and the contribution of the company to enhance the reputation of both partners in the international arena.
  • Cooperation with academia contributed to a number of development achievements at Lek and Novartis.
6. 12. 2016

On today's formal sitting of the senate of the University of Ljubljana, Vojmir Urlep, President of the Board of Management of Lek and Novartis Country President, Slovenia, received a plaque »Pro Universitate Labacensi« based on the proposal of the Faculty of Pharmacy. The University of Ljubljana conferrs this award to individuals and organizations, who through their assets or work, significantly contribute to the development of material possibilities of the University or to the training of its associates.

The bestowal of the plaque was accompanied by the following reasoning: “For the past 25 years, Vojmir Urlep has been an external consultant of the University of Ljubljana for the Pharmacy program. He has been successfully transferring his knowledge and experience from the competitive business world of the pharmaceutical industry to the academic environment, encouraging development as well as the exchange of knowledge and expertise, increasing the international competitiveness of graduates at the Faculty of Pharmacy of the University of Ljubljana and at the same time providing training and increasing employee competencies. With his international activities he raises the reputation of the University of Ljubljana internationally and opens opportunities for cooperation.”

Vojmir Urlep has performed the function of the President of the Board of Management of Lek, a Sandoz company, since August 2007 and is at the same time a guest lecturer in marketing at the Faculty of Pharmacy in Ljubljana. He is also the President of the Supervisory Board of the Chamber of Commerce and Industry of Slovenia, a member of the Executive Board of The Managers’ Association of Slovenia, a member of the organizing committee for the preparation of the annual congress of pharmacists at the Slovenian Pharmaceutical Society, a member of the Strategic Council for Internationalization and the President of the strategic group of foreign-owned companies at the Chamber of Commerce and Industry of Slovenia.

»The biggest competitive advantage that the Slovenian economy can generate if properly developed and nurtured, is knowledge. At Lek, we realized this long a time ago and our entire development has been based on this realization. It is the exceptional knowledge and experience that enabled us to be successful also within one of the largest pharmaceutical companies in the world. However, we were clearly aware that we could not do everything on our own. Therefore, we were looking for cooperation with institutions, which operate, just as we do, on the basis of knowledge. Our cooperation with the University of Ljubljana and its members has throughout these years evolved into a true partnership, which is an excellent foundation to build on also in the future. At the same time I am grateful that I was given the privilege to share as a guest lecturer some of my own knowledge and experience with future generations,« added Vojmir Urlep. 

* * *

Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.

Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).
For further details visit www.sandoz.com/makingaccesshappen

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32